Argenica Therapeutics Ltd has released a press release.
Appendix 4E & Annual Report to 30 June 2025
Filed with ASX ·
6ix hasn’t read this filing yet.
Argenica Therapeutics Ltd on 6ix
Story so far
Earlier from Argenica Therapeutics
- Argenica Receives IND Feedback From FDA
- Argenica Awarded Federal Government Funding
- Argenica to Progress Clinical Development in TBI
- Update on Investigational New Drug Application
- New US Patent for Surgical Stroke
Later from Argenica Therapeutics
- Trading Halt
- Topline Phase 2 Trial Results of ARG-007 in AIS Patients
- Phase 2 Trial Promising Improvements in Functional Outcomes
- ARG-007 Efficacious Dose Validated in New Preclinical Study
- Positive TNK Study Results Fulfil Key FDA Requirement
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics